An update on current and emerging treatments for pulmonary arterial hypertension in childhood and adolescence

References

• Simonneau G, Gatzoulis MA, Adatia I, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2013;62(25 Suppl):D34–41.
   PubMed Web of Science ®Google Scholar
• van Loon RL, Roofthooft MT, Hillege HL, et al. Pediatric pulmonary hypertension in the Netherlands: epidemiology and characterization during the period 1991 to 2005. Circulation. 2011;124(16):1755–1764.
   PubMed Web of Science ®Google Scholar
• Berger RM, Beghetti M, Humpl T, et al. Clinical features of paediatric pulmonary hypertension: a registry study. Lancet. 2012;379(9815):537–546.
   PubMed Web of Science ®Google Scholar
• Engelfriet PM, Duffels MG, Moller T, et al. Pulmonary arterial hypertension in adults born with a heart septal defect: the Euro heart survey on adult congenital heart disease. Heart. 2007;93(6):682–687.
   PubMed Web of Science ®Google Scholar
• Galie N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the diagnosis and treatment of pulmonary hypertension of the European society of cardiology (ESC) and the European respiratory society (ERS): endorsed by: association for European paediatric and congenital cardiology (AEPC), international society for heart and lung transplantation (ISHLT). Eur Respir J. 2015;46(4):903–975.
   PubMed Web of Science ®Google Scholar
• Kulik TJ. Pulmonary blood flow and pulmonary hypertension: is the pulmonary circulation flowophobic or flowophilic? Pulm Circ. 2012;2(3):327–339.
   PubMedGoogle Scholar
• D’Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med. 1991;115(5):343–349.
   PubMed Web of Science ®Google Scholar
• Haworth SG, Hislop AA. Treatment and survival in children with pulmonary arterial hypertension: the UK pulmonary hypertension service for children 2001-2006. Heart. 2009;95(4):312–317.
   PubMed Web of Science ®Google Scholar
• Barst RJ, McGoon MD, Elliott CG, et al. Survival in childhood pulmonary arterial hypertension: insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management. Circulation. 2012;125(1):113–122.
   PubMed Web of Science ®Google Scholar
• van Loon RL, Roofthooft MT, Delhaas T, et al. Outcome of pediatric patients with pulmonary arterial hypertension in the era of new medical therapies. Am J Cardiol. 2010;106(1):117–124.
   PubMed Web of Science ®Google Scholar
• Zijlstra WMH, Douwes JM, Rosenzweig EB, et al. Survival differences in pediatric pulmonary arterial hypertension: clues to a better understanding of outcome and optimal treatment strategies. J Am Coll Cardiol. 2014;63(20):2159–2169.
   PubMed Web of Science ®Google Scholar
• Galie N, Manes A, Negro L, et al. A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J. 2009;30(4):394–403.
   PubMed Web of Science ®Google Scholar
• Liu HL, Chen XY, Li JR, et al. Efficacy and safety of pulmonary arterial hypertension-specific therapy in pulmonary arterial hypertension: a meta-analysis of randomized controlled trials. Chest. 2016;150(2):353–366.
   PubMed Web of Science ®Google Scholar
• Rosenzweig EB, Feinstein JA, Humpl T, et al. Pulmonary arterial hypertension in children: diagnostic work-up and challenges. Prog Pediatr Cardiol. 2009;27(1):4–11.
   PubMedGoogle Scholar
• Beghetti M, Berger RM, Schulze-Neick I, et al. Diagnostic evaluation of paediatric pulmonary hypertension in current clinical practice. Eur Respir J. 2013;42(3):689–700.
   PubMed Web of Science ®Google Scholar
• Beghetti M, Schulze-Neick I, Berger RM, et al. Haemodynamic characterisation and heart catheterisation complications in children with pulmonary hypertension: insights from the Global TOPP Registry (tracking outcomes and practice in paediatric pulmonary hypertension). Int J Cardiol. 2016;203:325–330.
   PubMed Web of Science ®Google Scholar
• Barst RJ, Maislin G, Fishman AP. Vasodilator therapy for primary pulmonary hypertension in children. Circulation. 1999;99(9):1197–1208.
   PubMed Web of Science ®Google Scholar
• Sitbon O, Humbert M, Jais X, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation. 2005;111(23):3105–3111.
   PubMed Web of Science ®Google Scholar
• Douwes JM, Humpl T, Bonnet D, et al. Acute vasodilator response in pediatric pulmonary arterial hypertension: current clinical practice from the TOPP registry. J Am Coll Cardiol. 2016;67(11):1312–1323.
   PubMed Web of Science ®Google Scholar
• Douwes JM, van Loon RL, Hoendermis ES, et al. Acute pulmonary vasodilator response in paediatric and adult pulmonary arterial hypertension: occurrence and prognostic value when comparing three response criteria. Eur Heart J. 2011;32(24):3137–3146.
   PubMed Web of Science ®Google Scholar
• Ivy DD, Abman SH, Barst RJ, et al. Pediatric pulmonary hypertension. J Am Coll Cardiol. 2013;62(25 Suppl):D117–26.
   PubMed Web of Science ®Google Scholar
• Apitz C, Hansmann G, Schranz D. Hemodynamic assessment and acute pulmonary vasoreactivity testing in the evaluation of children with pulmonary vascular disease. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European paediatric pulmonary vascular disease network, endorsed by ISHLT and DGPK. Heart. 2016;102(Suppl 2):ii23–9.
   PubMedGoogle Scholar
• Yung D, Widlitz AC, Rosenzweig EB, et al. Outcomes in children with idiopathic pulmonary arterial hypertension. Circulation. 2004;110(6):660–665.
   PubMed Web of Science ®Google Scholar
• Humpl T, Reyes JT, Holtby H, et al. Beneficial effect of oral sildenafil therapy on childhood pulmonary arterial hypertension: twelve-month clinical trial of a single-drug, open-label, pilot study. Circulation. 2005;111(24):3274–3280.
   PubMed Web of Science ®Google Scholar
• Abrams D, Schulze-Neick I, Magee AG. Sildenafil as a selective pulmonary vasodilator in childhood primary pulmonary hypertension. Heart. 2000;84(2):E4.
   PubMedGoogle Scholar
• Karatza AA, Bush A, Magee AG. Safety and efficacy of sildenafil therapy in children with pulmonary hypertension. Int J Cardiol. 2005;100(2):267–273.
   PubMed Web of Science ®Google Scholar
• Humpl T, Reyes JT, Erickson S, et al. Sildenafil therapy for neonatal and childhood pulmonary hypertensive vascular disease. Cardiol Young. 2011;21(2):187–193.
   PubMed Web of Science ®Google Scholar
• Barst RJ, Ivy DD, Gaitan G, et al. A randomized, double-blind, placebo-controlled, dose-ranging study of oral sildenafil citrate in treatment-naive children with pulmonary arterial hypertension. Circulation. 2012;125(2):324–334.
   PubMed Web of Science ®Google Scholar
• Abman SH, Hansmann G, Archer SL, et al. Pediatric pulmonary hypertension: guidelines from the American heart association and American thoracic society. Circulation. 2015;132(21):2037–2099.
   PubMed Web of Science ®Google Scholar
• Abman SH, Kinsella JP, Rosenzweig EB, et al. Implications of the U.S. food and drug administration warning against the use of sildenafil for the treatment of pediatric pulmonary hypertension. Am J Respir Crit Care Med. 2013;187(6):572–575.
   PubMed Web of Science ®Google Scholar
• Galie N, Brundage BH, Ghofrani HA, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation. 2009;119(22):2894–2903.
   PubMed Web of Science ®Google Scholar
• Takatsuki S, Calderbank M, Ivy DD. Initial experience with tadalafil in pediatric pulmonary arterial hypertension. Pediatr Cardiol. 2012;33(5):683–688.
   PubMed Web of Science ®Google Scholar
• Sabri MR, Beheshtian E. Comparison of the therapeutic and side effects of tadalafil and sildenafil in children and adolescents with pulmonary arterial hypertension. Pediatr Cardiol. 2014;35(4):699–704.
   PubMed Web of Science ®Google Scholar
• Ghofrani HA, Galie N, Grimminger F, et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med. 2013;369(4):330–340.
   PubMed Web of Science ®Google Scholar
• Spreemann T, Bertram H, Happel CM, et al. First-in-child use of the oral soluble guanylate cyclase stimulator riociguat in pulmonary arterial hypertension. Pulm Circ. 2018;8(1):2045893217743123.
   Web of Science ®Google Scholar
• Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002;346(12):896–903.
   PubMed Web of Science ®Google Scholar
• Galie N, Beghetti M, Gatzoulis MA, et al. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation. 2006;114(1):48–54.
   PubMed Web of Science ®Google Scholar
• Rosenzweig EB, Ivy DD, Widlitz A, et al. Effects of long-term bosentan in children with pulmonary arterial hypertension. J Am Coll Cardiol. 2005;46(4):697–704.
   PubMed Web of Science ®Google Scholar
• Ivy DD, Rosenzweig EB, Lemarie JC, et al. Long-term outcomes in children with pulmonary arterial hypertension treated with bosentan in real-world clinical settings. Am J Cardiol. 2010;106(9):1332–1338.
   PubMed Web of Science ®Google Scholar
• van Loon RL, Hoendermis ES, Duffels MG, et al. Long-term effect of bosentan in adults versus children with pulmonary arterial hypertension associated with systemic-to-pulmonary shunt: does the beneficial effect persist? Am Heart J. 2007;154(4):776–782.
   PubMed Web of Science ®Google Scholar
• Beghetti M, Haworth SG, Bonnet D, et al. Pharmacokinetic and clinical profile of a novel formulation of bosentan in children with pulmonary arterial hypertension: the FUTURE-1 study. Br J Clin Pharmacol. 2009;68(6):948–955.
   PubMed Web of Science ®Google Scholar
• Berger RM, Haworth SG, Bonnet D, et al. FUTURE-2: results from an open-label, long-term safety and tolerability extension study using the pediatric FormUlation of bosenTan in pUlmonary arterial hypeRtEnsion. Int J Cardiol. 2016;202:52–58.
   PubMed Web of Science ®Google Scholar
• Beghetti M, Hoeper MM, Kiely DG, et al. Safety experience with bosentan in 146 children 2-11 years old with pulmonary arterial hypertension: results from the European postmarketing surveillance program. Pediatr Res. 2008;64(2):200–204.
   PubMed Web of Science ®Google Scholar
• Pulido T, Adzerikho I, Channick RN, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013;369(9):809–818.
   PubMed Web of Science ®Google Scholar
• Galie N, Olschewski H, Oudiz RJ, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation. 2008;117(23):3010–3019.
   PubMed Web of Science ®Google Scholar
• Zuckerman WA, Leaderer D, Rowan CA, et al. Ambrisentan for pulmonary arterial hypertension due to congenital heart disease. Am J Cardiol. 2011;107(9):1381–1385.
   PubMed Web of Science ®Google Scholar
• Takatsuki S, Rosenzweig EB, Zuckerman W, et al. Clinical safety, pharmacokinetics, and efficacy of ambrisentan therapy in children with pulmonary arterial hypertension. Pediatr Pulmonol. 2013;48(1):27–34.
   PubMed Web of Science ®Google Scholar
• Christman BW, McPherson CD, Newman JH, et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med. 1992;327(2):70–75.
   PubMed Web of Science ®Google Scholar
• Lammers AE, Hislop AA, Flynn Y, et al. Epoprostenol treatment in children with severe pulmonary hypertension. Heart. 2007;93(6):739–743.
   PubMed Web of Science ®Google Scholar
• Barst RJ, Galie N, Naeije R, et al. Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil. Eur Respir J. 2006;28(6):1195–1203.
   PubMed Web of Science ®Google Scholar
• Levy M, Del Cerro MJ, Nadaud S, et al. Safety, efficacy and management of subcutaneous treprostinil infusions in the treatment of severe pediatric pulmonary hypertension. Int J Cardiol. 2018;264:153–157.
   PubMed Web of Science ®Google Scholar
• Gomberg-Maitland M, Tapson VF, Benza RL, et al. Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension. Am J Respir Crit Care Med. 2005;172(12):1586–1589.
   PubMed Web of Science ®Google Scholar
• Ivy DD, Claussen L, Doran A. Transition of stable pediatric patients with pulmonary arterial hypertension from intravenous epoprostenol to intravenous treprostinil. Am J Cardiol. 2007;99(5):696–698.
   PubMed Web of Science ®Google Scholar
• Krishnan U, Takatsuki S, Ivy DD, et al. Effectiveness and safety of inhaled treprostinil for the treatment of pulmonary arterial hypertension in children. Am J Cardiol. 2012;110(11):1704–1709.
   PubMed Web of Science ®Google Scholar
• Jing ZC, Parikh K, Pulido T, et al. Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial. Circulation. 2013;127(5):624–633.
   PubMed Web of Science ®Google Scholar
• Olschewski H, Simonneau G, Galie N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med. 2002;347(5):322–329.
   PubMed Web of Science ®Google Scholar
• Ivy DD, Doran AK, Smith KJ, et al. Short- and long-term effects of inhaled iloprost therapy in children with pulmonary arterial hypertension. J Am Coll Cardiol. 2008;51(2):161–169.
   PubMed Web of Science ®Google Scholar
• Sitbon O, Channick R, Chin KM, et al. Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med. 2015;373(26):2522–2533.
   PubMed Web of Science ®Google Scholar
• Geerdink LM, Bertram H, Hansmann G. First-in-child use of the oral selective prostacyclin IP receptor agonist selexipag in pulmonary arterial hypertension. Pulm Circ. 2017;7(2):551–554.
   PubMed Web of Science ®Google Scholar
• Gallotti R, Drogalis-Kim DE, Satou G, et al. Single-center experience using selexipag in a pediatric population. Pediatr Cardiol. 2017;38(7):1405–1409.
   PubMed Web of Science ®Google Scholar
• Galie N, Barbera JA, Frost AE, et al. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N Engl J Med. 2015;373(9):834–844.
   PubMed Web of Science ®Google Scholar
• Sitbon O, Sattler C, Bertoletti L, et al. Initial dual oral combination therapy in pulmonary arterial hypertension. Eur Respir J. 2016;47(6):1727–1736.
   PubMed Web of Science ®Google Scholar
• Humpl T, Berger RMF, Austin ED, et al. Treatment initiation in paediatric pulmonary hypertension: insights from a multinational registry. Cardiol Young. 2017;27(6):1123–1132.
   PubMed Web of Science ®Google Scholar
• Sitbon O, Jais X, Savale L, et al. Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study. Eur Respir J. 2014;43(6):1691–1697.
   PubMed Web of Science ®Google Scholar
• Douwes JM, Berger RMF. Pediatric pulmonary arterial hypertension: on the eve of growing up. Curr Opin Pulm Med. 2017;23(5):398–403.
   PubMed Web of Science ®Google Scholar
• Ploegstra MJ, Douwes JM, Roofthooft MT, et al. Identification of treatment goals in paediatric pulmonary arterial hypertension. Eur Respir J. 2014;44(6):1616–1626.
   PubMed Web of Science ®Google Scholar
• Truong U, Patel S, Kheyfets V, et al. Non-invasive determination by cardiovascular magnetic resonance of right ventricular-vascular coupling in children and adolescents with pulmonary hypertension. J Cardiovasc Magn Reson. 2015;17:81.
   PubMed Web of Science ®Google Scholar
• Leberkuhne LJ, Ploegstra MJ, Douwes JM, et al. Serially measured uric acid levels predict disease severity and outcome in pediatric pulmonary arterial hypertension. Am J Respir Crit Care Med. 2017;195(3):401–404.
   PubMed Web of Science ®Google Scholar
• Douwes JM, Hegeman AK, van der Krieke MB, et al. Six-minute walking distance and decrease in oxygen saturation during the six-minute walk test in pediatric pulmonary arterial hypertension. Int J Cardiol. 2016;202:34–39.
   PubMed Web of Science ®Google Scholar
• Ploegstra MJ, Ivy DD, Wheeler JG, et al. Growth in children with pulmonary arterial hypertension: a longitudinal retrospective multiregistry study. Lancet Respir Med. 2016;4(4):281–290.
   PubMed Web of Science ®Google Scholar
• Ploegstra MJ, Arjaans S, Zijlstra WMH, et al. Clinical worsening as composite study end point in pediatric pulmonary arterial hypertension. Chest. 2015;148(3):655–666.
   PubMed Web of Science ®Google Scholar
• Benden C, Goldfarb SB, Edwards LB, et al. The registry of the international society for heart and lung transplantation: seventeenth official pediatric lung and heart-lung transplantation report–2014; focus theme: retransplantation. J Heart Lung Transplant. 2014;33(10):1025–1033.
   PubMedGoogle Scholar
• Chiu JS, Zuckerman WA, Turner ME, et al. Balloon atrial septostomy in pulmonary arterial hypertension: effect on survival and associated outcomes. J Heart Lung Transplant. 2015;34(3):376–380.
   PubMed Web of Science ®Google Scholar
• Kerstein D, Levy PS, Hsu DT, et al. Blade balloon atrial septostomy in patients with severe primary pulmonary hypertension. Circulation. 1995;91(7):2028–2035.
   PubMed Web of Science ®Google Scholar
• Micheletti A, Hislop AA, Lammers A, et al. Role of atrial septostomy in the treatment of children with pulmonary arterial hypertension. Heart. 2006;92(7):969–972.
   PubMed Web of Science ®Google Scholar
• Baruteau AE, Serraf A, Levy M, et al. Potts shunt in children with idiopathic pulmonary arterial hypertension: long-term results. Ann Thorac Surg. 2012;94(3):817–824.
   PubMed Web of Science ®Google Scholar
• Baruteau AE, Belli E, Boudjemline Y, et al. Palliative potts shunt for the treatment of children with drug-refractory pulmonary arterial hypertension: updated data from the first 24 patients. Eur J Cardiothorac Surg. 2015;47(3):e105–10.
   PubMed Web of Science ®Google Scholar
• Grady RM, Eghtesady P. Potts shunt and pediatric pulmonary hypertension: what we have learned. Ann Thorac Surg. 2016;101(4):1539–1543.
   PubMed Web of Science ®Google Scholar
• Gorbachevsky SV, Shmalts AA, Barishnikova IY, et al. Potts shunt in children with pulmonary arterial hypertension: institutional experience. Interact Cardiovasc Thorac Surg. 2017;25(4):595–599.
   PubMed Web of Science ®Google Scholar
• Morchi GS, Ivy DD, Duster MC, et al. Sildenafil increases systemic saturation and reduces pulmonary artery pressure in patients with failing fontan physiology. Congenit Heart Dis. 2009;4(2):107–111.
   PubMed Web of Science ®Google Scholar
• Bowater SE, Weaver RA, Thorne SA, et al. The safety and effects of bosentan in patients with a fontan circulation. Congenit Heart Dis. 2012;7(3):243–249.
   PubMed Web of Science ®Google Scholar
• Hebert A, Mikkelsen UR, Thilen U, et al. Bosentan improves exercise capacity in adolescents and adults after fontan operation: the TEMPO (treatment with endothelin receptor antagonist in fontan patients, a randomized, placebo-controlled, double-blind study measuring peak oxygen consumption) study. Circulation. 2014;130(23):2021–2030.
   PubMed Web of Science ®Google Scholar
• Krishnan U, Rosenzweig EB. Pulmonary hypertension in chronic lung disease of infancy. Curr Opin Pediatr. 2015;27(2):177–183.
   PubMed Web of Science ®Google Scholar
• Hilgendorff A, Apitz C, Bonnet D, et al. Pulmonary hypertension associated with acute or chronic lung diseases in the preterm and term neonate and infant. The European paediatric pulmonary vascular disease network, endorsed by ISHLT and DGPK. Heart. 2016;102(Suppl 2):ii49–56.
   PubMedGoogle Scholar